For patients with metastatic non-triple-negative breast cancer, endocrine therapy or HER2-targeted therapy plays an important role in the treatment besides chemotherapy, however nearly all patients will eventually develop drug resistance. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.